Developing and making innovative tools for the production and purification of genetically engineered proteins ised in life science research, TriAltus is an early-stage start-up biotechnology company. The firm's patented core technology is an engineered protein tag system that binds with 100,000x higher affinity than alternatives, resulting in 10-80x yield improvement and 99% purity in a single step. Clients to date already include researchers at Harvard, Mayo Clinic, and Scripps, as well as Pharma scientists at Merck, Moderna and Amgen.
